Top Three Treatments for Eosinophilic Esophagitis Dysphagia Relief

Eosinophilic esophagitis (EoE) presents a significant clinical challenge, with dysphagia being the most common and debilitating symptom. The underlying pathology involves an allergic inflammatory response within the esophageal mucosa, leading to fibrosis and stricture formation.¹ This chronic, immune-mediated disease is characterized by the infiltration of eosinophils into the esophageal lining, which can be triggered by specific food or environmental allergens. The prevalence of EoE has been increasing globally, affecting approximately 1 in 2,000 individuals, with a higher incidence in males and Caucasians.¹ Management strategies aim to control this inflammation, thereby alleviating symptoms and preventing disease progression. The current evidence supports three main therapeutic approaches: proton pump inhibitors (PPIs), topical corticosteroids, and dietary elimination.²

Pharmacological and Dietary Interventions for EoE

Proton pump inhibitors (PPIs) are often the initial therapeutic choice for EoE. While traditionally used for acid suppression, PPIs have demonstrated anti-inflammatory effects in the esophageal mucosa, independent of their acid-reducing properties.³ This anti-inflammatory action is particularly relevant in a subset of patients termed PPI-responsive esophageal eosinophilia (PPI-REE), who exhibit clinical and histological features indistinguishable from EoE but respond to PPI therapy.³ Studies indicate that PPIs can induce histological remission (defined as fewer than 15 eosinophils per high-power field) in approximately 50% of adult EoE patients.⁴ Symptomatic improvement, including relief from dysphagia, is observed in a similar proportion of patients. The mechanism is thought to involve inhibition of eotaxin-3 expression and modulation of tight junction proteins, which are crucial in maintaining esophageal barrier integrity and regulating eosinophil recruitment.³ The convenience of oral administration and a favorable safety profile make PPIs an attractive first-line option, particularly for patients with co-existing gastroesophageal reflux disease (GERD) symptoms.

Topical corticosteroids, such as fluticasone propionate and budesonide, are highly effective in treating EoE. These agents are administered orally, typically as a swallowed slurry or spray, allowing direct contact with the esophageal mucosa.⁵ This localized delivery minimizes systemic absorption and reduces the risk of systemic corticosteroid side effects. Fluticasone propionate, delivered via a metered-dose inhaler and swallowed, has shown histological remission rates ranging from 70% to 80% in both adult and paediatric populations.⁶ Budesonide, often formulated as an oral viscous slurry, demonstrates similar efficacy, with remission rates also in the 70-80% range.⁷ Both agents significantly improve dysphagia and other EoE symptoms, such as chest pain and food impaction. The main adverse event associated with topical corticosteroids is oral candidiasis, which occurs in approximately 5-10% of patients and is typically managed with antifungal therapy without requiring discontinuation of EoE treatment.^6,7

Dietary elimination therapy involves identifying and removing specific food allergens that trigger the inflammatory response in EoE. The most common approach is the six-food elimination diet (SFED), which removes milk, wheat, soy, egg, peanut/tree nuts, and fish/shellfish.⁸ This broad elimination diet has shown high efficacy, with histological remission rates of 70-75%.⁹ However, the SFED is restrictive and requires subsequent reintroduction of foods with endoscopic biopsies to identify specific triggers, which can be burdensome for patients.⁸ This process often involves multiple endoscopies over several months, impacting patient quality of life and adherence. A more targeted approach, such as allergy testing-directed elimination, has lower efficacy (approximately 40-50% remission) but is less restrictive, relying on skin prick tests or atopy patch tests to guide food removal.¹⁰ Elemental diets, consisting of amino acid-based formulas, are the most effective dietary therapy, achieving remission in over 90% of patients, but are generally reserved for severe cases or those unresponsive to other therapies due to their palatability and cost.¹¹ The significant commitment required for dietary therapies, particularly SFED, necessitates strong patient education and support to ensure compliance and successful outcomes.

The choice of therapy often depends on patient preference, disease severity, and response to initial treatment. While PPIs offer a convenient first-line option, topical corticosteroids provide higher remission rates. Dietary therapy, particularly SFED, is highly effective but demands significant patient adherence and diagnostic follow-up. Combination therapies are also employed in refractory cases, where patients do not achieve adequate control with monotherapy.¹² Emerging therapies, including biologics targeting specific inflammatory pathways, are also under investigation and may offer additional options for patients with difficult-to-treat EoE in the future. The long-term management of EoE often requires ongoing therapy to prevent symptom recurrence and esophageal remodeling.